ImmunovantInc Free Cash Flow vs Enterprise Value Analysis

IMVT Stock

USD 28.74 0.52 1.84%

ImmunovantInc financial indicator trend analysis is infinitely more than just investigating ImmunovantInc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ImmunovantInc is a good investment. Please check the relationship between ImmunovantInc Free Cash Flow and its Enterprise Value accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.

Free Cash Flow vs Enterprise Value

Free Cash Flow vs Enterprise Value Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ImmunovantInc Free Cash Flow account and Enterprise Value. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between ImmunovantInc's Free Cash Flow and Enterprise Value is -0.04. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Enterprise Value in the same time period over historical financial statements of ImmunovantInc, assuming nothing else is changed. The correlation between historical values of ImmunovantInc's Free Cash Flow and Enterprise Value is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of ImmunovantInc are associated (or correlated) with its Enterprise Value. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Enterprise Value has no effect on the direction of Free Cash Flow i.e., ImmunovantInc's Free Cash Flow and Enterprise Value go up and down completely randomly.

Correlation Coefficient

-0.04

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Enterprise Value

Enterprise Value (or EV) is usually referred to as ImmunovantInc theoretical takeover price. In the event of an acquisition, an acquirer would have to take on ImmunovantInc debt, but would also pocket its cash. Enterprise Value is more accurate representation of ImmunovantInc value than its market capitalization because it takes into account all of ImmunovantInc existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.

Most indicators from ImmunovantInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ImmunovantInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.At this time, ImmunovantInc's Tax Provision is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 78.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 30.1 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	156.0M	208.3M	239.5M	123.8M
Research Development	101.8M	160.3M	184.3M	98.9M

Total Operating Expenses Research Development

ImmunovantInc fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Accounts Payable	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Other Current Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Deferred Long Term Liab	Net Invested Capital
Total Assets		0.89	1.0	1.0	0.56	0.91	0.91	0.9	1.0	0.71	0.83	0.92	-0.9	-0.98	-0.88	1.0	0.92	0.92	1.0	0.2	0.98	0.02	0.97	0.73	-0.9	1.0
Total Current Liabilities	0.89		0.89	0.89	0.43	0.98	0.99	1.0	0.89	0.61	0.98	0.74	-0.86	-0.91	-0.98	0.91	0.74	0.84	0.91	0.1	0.94	0.0	0.94	0.91	-0.89	0.91
Total Stockholder Equity	1.0	0.89		1.0	0.56	0.91	0.91	0.9	1.0	0.71	0.82	0.93	-0.9	-0.98	-0.88	1.0	0.93	0.91	1.0	0.19	0.97	0.02	0.97	0.72	-0.9	1.0
Net Tangible Assets	1.0	0.89	1.0		0.56	0.91	0.91	0.9	1.0	0.71	0.82	0.93	-0.9	-0.98	-0.88	1.0	0.93	0.91	1.0	0.19	0.97	0.01	0.97	0.72	-0.9	1.0
Accounts Payable	0.56	0.43	0.56	0.56		0.35	0.36	0.44	0.56	0.36	0.22	0.52	-0.41	-0.57	-0.31	0.56	0.52	0.39	0.56	0.91	0.43	0.0	0.43	0.02	-0.38	0.55
Common Stock Shares Outstanding	0.91	0.98	0.91	0.91	0.35		1.0	0.99	0.91	0.66	0.98	0.81	-0.88	-0.93	-0.97	0.93	0.81	0.86	0.93	-0.01	0.95	-0.01	0.94	0.92	-0.91	0.93
Other Stockholder Equity	0.91	0.99	0.91	0.91	0.36	1.0		0.99	0.91	0.63	0.98	0.8	-0.86	-0.93	-0.98	0.93	0.8	0.84	0.93	0.0	0.95	-0.06	0.95	0.93	-0.89	0.93
Total Liab	0.9	1.0	0.9	0.9	0.44	0.99	0.99		0.91	0.63	0.97	0.76	-0.87	-0.92	-0.98	0.92	0.76	0.84	0.92	0.1	0.94	0.0	0.94	0.9	-0.9	0.92
Total Current Assets	1.0	0.89	1.0	1.0	0.56	0.91	0.91	0.91		0.7	0.83	0.92	-0.9	-0.98	-0.88	1.0	0.92	0.92	1.0	0.2	0.98	0.02	0.97	0.73	-0.9	1.0
Short Long Term Debt Total	0.71	0.61	0.71	0.71	0.36	0.66	0.63	0.63	0.7		0.57	0.76	-0.89	-0.75	-0.54	0.72	0.78	0.84	0.72	0.08	0.69	0.59	0.6	0.46	-0.88	0.72
Other Current Liab	0.83	0.98	0.82	0.82	0.22	0.98	0.98	0.97	0.83	0.57		0.67	-0.83	-0.84	-0.98	0.84	0.67	0.81	0.84	-0.11	0.91	0.01	0.9	0.98	-0.87	0.84
Property Plant And Equipment Net	0.92	0.74	0.93	0.93	0.52	0.81	0.8	0.76	0.92	0.76	0.67		-0.81	-0.94	-0.72	0.93	1.0	0.79	0.93	0.14	0.85	-0.05	0.82	0.57	-0.81	0.93
Current Deferred Revenue	-0.9	-0.86	-0.9	-0.9	-0.41	-0.88	-0.86	-0.87	-0.9	-0.89	-0.83	-0.81		0.91	0.83	-0.9	-0.82	-0.98	-0.9	-0.07	-0.92	-0.4	-0.87	-0.73	1.0	-0.9
Net Debt	-0.98	-0.91	-0.98	-0.98	-0.57	-0.93	-0.93	-0.92	-0.98	-0.75	-0.84	-0.94	0.91		0.89	-0.99	-0.94	-0.88	-0.99	-0.2	-0.95	-0.01	-0.94	-0.74	0.91	-0.99
Retained Earnings	-0.88	-0.98	-0.88	-0.88	-0.31	-0.97	-0.98	-0.98	-0.88	-0.54	-0.98	-0.72	0.83	0.89		-0.89	-0.72	-0.82	-0.89	0.04	-0.94	0.07	-0.95	-0.94	0.86	-0.89
Cash	1.0	0.91	1.0	1.0	0.56	0.93	0.93	0.92	1.0	0.72	0.84	0.93	-0.9	-0.99	-0.89		0.93	0.91	1.0	0.19	0.98	0.01	0.97	0.74	-0.91	1.0
Non Current Assets Total	0.92	0.74	0.93	0.93	0.52	0.81	0.8	0.76	0.92	0.78	0.67	1.0	-0.82	-0.94	-0.72	0.93		0.8	0.93	0.14	0.85	-0.01	0.82	0.57	-0.82	0.93
Non Currrent Assets Other	0.92	0.84	0.91	0.91	0.39	0.86	0.84	0.84	0.92	0.84	0.81	0.79	-0.98	-0.88	-0.82	0.91	0.8		0.91	0.06	0.94	0.39	0.9	0.71	-0.97	0.91
Cash And Short Term Investments	1.0	0.91	1.0	1.0	0.56	0.93	0.93	0.92	1.0	0.72	0.84	0.93	-0.9	-0.99	-0.89	1.0	0.93	0.91		0.19	0.98	0.01	0.97	0.74	-0.91	1.0
Net Receivables	0.2	0.1	0.19	0.19	0.91	-0.01	0.0	0.1	0.2	0.08	-0.11	0.14	-0.07	-0.2	0.04	0.19	0.14	0.06	0.19		0.06	0.04	0.08	-0.31	-0.04	0.18
Common Stock Total Equity	0.98	0.94	0.97	0.97	0.43	0.95	0.95	0.94	0.98	0.69	0.91	0.85	-0.92	-0.95	-0.94	0.98	0.85	0.94	0.98	0.06		0.07	0.99	0.83	-0.93	0.98
Non Current Liabilities Total	0.02	0.0	0.02	0.01	0.0	-0.01	-0.06	0.0	0.02	0.59	0.01	-0.05	-0.4	-0.01	0.07	0.01	-0.01	0.39	0.01	0.04	0.07		-0.03	-0.07	-0.37	0.01
Capital Surpluse	0.97	0.94	0.97	0.97	0.43	0.94	0.95	0.94	0.97	0.6	0.9	0.82	-0.87	-0.94	-0.95	0.97	0.82	0.9	0.97	0.08	0.99	-0.03		0.84	-0.88	0.97
Other Current Assets	0.73	0.91	0.72	0.72	0.02	0.92	0.93	0.9	0.73	0.46	0.98	0.57	-0.73	-0.74	-0.94	0.74	0.57	0.71	0.74	-0.31	0.83	-0.07	0.84		-0.78	0.74
Deferred Long Term Liab	-0.9	-0.89	-0.9	-0.9	-0.38	-0.91	-0.89	-0.9	-0.9	-0.88	-0.87	-0.81	1.0	0.91	0.86	-0.91	-0.82	-0.97	-0.91	-0.04	-0.93	-0.37	-0.88	-0.78		-0.91
Net Invested Capital	1.0	0.91	1.0	1.0	0.55	0.93	0.93	0.92	1.0	0.72	0.84	0.93	-0.9	-0.99	-0.89	1.0	0.93	0.91	1.0	0.18	0.98	0.01	0.97	0.74	-0.91

Click cells to compare fundamentals

ImmunovantInc Account Relationship Matchups

ImmunovantInc fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	109.4M	412.5M	515.6M	405.8M	466.7M	264.7M
Total Current Liabilities	15.3M	18.8M	44.5M	43.3M	49.8M	52.3M
Total Stockholder Equity	94.1M	391.5M	469.8M	362.5M	416.9M	241.3M
Net Tangible Assets	94.1M	391.5M	469.8M	362.5M	416.9M	242.7M
Accounts Payable	1.2M	2.4M	18.6M	1.4M	1.6M	1.5M
Common Stock Shares Outstanding	43.2M	87.8M	109.7M	123.1M	141.5M	148.6M
Other Stockholder Equity	185.3M	590.4M	824.8M	928.0M	1.1B	1.1B
Total Liab	15.3M	21.0M	45.7M	43.3M	49.8M	52.3M
Total Current Assets	109.1M	409.0M	512.9M	404.3M	465.0M	263.2M
Short Long Term Debt Total	3.2M	3.4M	2.4M	1.2M	1.4M	2.3M
Other Current Liab	14.1M	15.2M	24.7M	40.8M	46.9M	49.2M
Property Plant And Equipment Net	65K	3.5M	2.6M	1.5M	1.7M	1.7M
Net Debt	(97.4M)	(396.7M)	(491.5M)	(375.3M)	(337.8M)	(354.7M)
Retained Earnings	(91.2M)	(198.7M)	(355.4M)	(566.3M)	(509.7M)	(484.2M)
Cash	100.6M	400.1M	493.8M	376.5M	433.0M	301.7M
Non Current Assets Total	311K	3.5M	2.6M	1.5M	1.7M	1.8M
Cash And Short Term Investments	100.6M	400.1M	493.8M	376.5M	433.0M	301.7M
Net Receivables	3.0M	548K	12.9M	885K	1.0M	966.9K
Common Stock Total Equity	5K	10K	12K	13K	15.0K	8.9K
Liabilities And Stockholders Equity	109.4M	412.5M	515.6M	405.8M	466.7M	317.6M
Non Current Liabilities Total	14.1M	2.2M	1.2M	47K	42.3K	40.2K
Capital Surpluse	185.3M	590.4M	824.8M	928.0M	1.1B	556.3M
Other Current Assets	5.5M	8.3M	6.3M	26.9M	31.0M	32.5M
Net Invested Capital	94.1M	391.5M	469.8M	362.5M	416.9M	290.0M
Capital Stock	5K	10K	12K	13K	15.0K	8.9K
Net Working Capital	93.8M	390.2M	468.4M	361.0M	415.2M	288.9M
Short Term Debt	3.2M	1.2M	1.1M	1.2M	1.1M	1.1M
Common Stock	5K	10K	12K	13K	15.0K	8.9K
Property Plant Equipment	65K	201K	330K	333K	383.0K	216.3K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether ImmunovantInc is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if ImmunovantInc Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Immunovantinc Stock. Highlighted below are key reports to facilitate an investment decision about Immunovantinc Stock:

How To Invest In ImmunovantInc

Details

Is ImmunovantInc Stock a good investment?

Details

What is ImmunovantInc's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.

You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for ImmunovantInc Stock analysis

When running ImmunovantInc's price analysis, check to measure ImmunovantInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunovantInc is operating at the current time. Most of ImmunovantInc's value examination focuses on studying past and present price action to predict the probability of ImmunovantInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunovantInc's price. Additionally, you may evaluate how the addition of ImmunovantInc to your portfolios can decrease your overall portfolio volatility.

	Transaction History View history of all your transactions and understand their impact on performance
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities

Is ImmunovantInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunovantInc. If investors know ImmunovantInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunovantInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.81)

Return On Assets

(0.27)

Return On Equity

(0.45)

The market value of ImmunovantInc is measured differently than its book value, which is the value of ImmunovantInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunovantInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunovantInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunovantInc's market value can be influenced by many factors that don't directly affect ImmunovantInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ImmunovantInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunovantInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunovantInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ImmunovantInc Free Cash Flow vs Enterprise Value Analysis

Free Cash Flow vs Enterprise Value

Free Cash Flow vs Enterprise Value Correlation Analysis

Correlation Coefficient

Free Cash Flow

Enterprise Value

ImmunovantInc fundamental ratios Correlations

ImmunovantInc Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ImmunovantInc fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for ImmunovantInc Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets

Net Invested Capital	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Non Currrent Assets Other	- 0.98	Current Deferred Revenue
Retained Earnings	- 0.98	Other Current Liab
Net Debt	- 0.98	Total Current Assets